FDA Clears EShunt System for Alzheimer’s Study
Federal regulators approved an investigational device exemption for a shunt designed to treat Alzheimer’s disease.
Updated on Oct. 31, 2026 in Alzheimer’s
Live Poll
Do you believe developing new, minimally invasive technologies is the best approach to treating Alzheimer's disease?
The FDA has granted an investigational device exemption for the eShunt System, a device CereVasc will test in patients with Alzheimer’s disease. The system is designed to divert cerebrospinal fluid to the venous system to potentially clear neurotoxins.
Why it matters
Researchers are investigating whether this approach supports the brain's natural ability to remove neurotoxins associated with the disease. This could provide a novel therapeutic path for the millions of Americans currently living with the condition.
The eShunt System uses a percutaneous transvenous-transdural approach to increase cerebrospinal fluid cycling. It aims to address the needs of the 7.4 million Americans age 65 and older currently affected by Alzheimer's.
The players
FDA
The United States government agency responsible for protecting public health by ensuring the safety and efficacy of medical devices and pharmaceuticals.
CereVasc
A medical device company based in Massachusetts focused on developing endovascular treatments for neurological conditions.
The details
The device operates by diverting cerebrospinal fluid into the venous system through a minimally invasive endovascular process. CereVasc, based in Massachusetts, previously completed enrollment in a separate clinical trial for normal pressure hydrocephalus.
Timeline
The patient population is projected to reach 13.8 million by 2060.
Health Landscape
The study builds upon the technical experience CereVasc gained during the STRIDE clinical trial for normal pressure hydrocephalus. This regulatory approval marks a transition for the technology into the broader field of neurodegenerative disease research.
This exemption allows for upcoming clinical trials, which may eventually offer new treatment avenues for those diagnosed with Alzheimer's. There is currently no change to existing care protocols or immediate consumer access to the device.
The takeaway
This development represents a shift toward surgical interventions in the management of neurodegenerative waste clearance. Patients and caregivers should remain focused on currently approved clinical practices while monitoring the progress of these upcoming trials.
Further reading
For more information on the current landscape of research and care, visit our Alzheimer’s section.
Source note: This article includes information reported by Pharmabiz.
Live Poll
Do you believe developing new, minimally invasive technologies is the best approach to treating Alzheimer's disease?
